Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 17/20 | 0.51 |
| ▸ | OPRM1 | P35372 | 15/20 | 0.49 |
| ▸ | HTR6 | P50406 | 2/20 | 0.43 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3405979 | 0.88 | OPRL1 (0.65) | OPRL1OPRM1 | |
| SCHEMBL3406231 | 0.85 | HTR6 (0.42) | OPRL1OPRM1HTR6GPR84 | |
| SCHEMBL3404197 | 0.83 | OPRL1 (0.48) | OPRL1OPRM1GPR84 | |
| SCHEMBL3428458 | 0.82 | OPRM1 (0.65) | OPRL1OPRM1GPR84 | |
| SCHEMBL3405007 | 0.81 | OPRL1 (0.49) | OPRL1OPRM1 | |
| SCHEMBL3431453 | 0.80 | OPRL1 (0.50) | OPRL1OPRM1 | |
| SCHEMBL3406604 | 0.80 | HTR6 (0.42) | OPRL1OPRM1HTR6GPR84 | |
| SCHEMBL3402459 | 0.79 | OPRL1 (0.41) | OPRL1OPRM1HTR6 | |
| SCHEMBL3405049 | 0.79 | OPRL1 (0.49) | OPRL1OPRM1 | |
| SCHEMBL3430225 | 0.78 | OPRL1 (0.52) | OPRL1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2254864-B1 | SUBSTITUTED 4-AMINOCYCLOHEXANE DERIVATIVES FOR THE TREATMENT OF PAIN | GRUENENTHAL GMBH (DE) | 2014-05-14 | — | — | EP | claimed |
| EP-2254864-A1 | SUBSTITUTED 4-AMINOCYCLOHEXANE DERIVATIVES FOR THE TREATMENT OF PAIN | Grünenthal GmbH (DE) | 2010-12-01 | — | — | EP | claimed |
| WO-2009106307-A1 | SUBSTITUTED 4-AMINOCYCLOHEXANE DERIVATIVES FOR THE TREATMENT OF PAIN | Grünenthal GmbH (DE) | 2009-09-03 | — | — | WO | claimed |
| US-20090215725-A1 | Substituted 4-aminocyclohexane derivatives | GRUNENTHAL GMBH (DE) | 2009-08-27 | — | — | US | claimed |
| EP-2254864-B1 | SUBSTITUTED 4-AMINOCYCLOHEXANE DERIVATIVES FOR THE TREATMENT OF PAIN | GRUENENTHAL GMBH (DE) | 2014-05-14 | — | — | EP | disclosed |
| US-20090215725-A1 | Substituted 4-aminocyclohexane derivatives | GRUNENTHAL GMBH (DE) | 2009-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215725-A1 | Substituted 4-aminocyclohexane derivatives | OPRL1, OPRD1, OPRK1 | OPRL1 1/4885OPRM1 7/4885HTR6 305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.